Business Wire

ViacomCBS Partners With Sky to Launch Paramount+ in Europe

Share

ViacomCBS Networks International (VCNI), a division of ViacomCBS Inc. (NASDAQ: VIAC, VIACA) and Sky, part of Comcast Corporation (NASDAQ: CMCSA), today announced that Paramount+ will launch on Sky platforms in the UK, Ireland, Italy, Germany, Switzerland and Austria (GSA) in 2022 as part of a new multi-year distribution agreement that also includes the extended carriage of ViacomCBS’ leading portfolio of pay TV channels and the renewal of Sky as an ad sales partner in select markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005410/en/

“We are thrilled to expand our long-standing partnership with Sky to continue delivering ViacomCBS’ leading portfolio of premium entertainment brands to Sky customers and importantly bring Paramount+ to new audiences in all Sky markets, including the UK, Ireland, Italy, and GSA,” said Raffaele Annecchino, President and Chief Executive Officer, ViacomCBS Networks International. “This transformative distribution deal is key to accelerating our global ambitions in streaming while also supporting Sky’s strategic objectives to better serve audiences with greater flexibility in how they consume our content across all platforms.”

Paramount+ is the latest in a series of apps to come to Sky Q adding more than 10,000 hours of content, further enhancing Sky’s aggregation strategy and enabling Sky customers to watch even more of the best content together in one place on the Sky Q platform.

Stephen van Rooyen, Executive VP & Chief Executive, UK & Europe at Sky said: “This is another example of how we are innovating for our customers and further aggregating all the best apps and content together in one place on Sky Q, giving them more great TV to watch than ever before. Paramount+ is an excellent service with a huge range of fantastic films and TV series, and our new, broader agreement with ViacomCBS will benefit both businesses.”

Upon launch, Sky Cinema subscribers will get the bonus of Paramount+ included at no additional cost, providing access to two fantastic services side by side with more than 10,000 hours of extra content for one affordable price. As part of this partnership, Paramount Pictures’ feature films will remain available on Sky Cinema in the UK and will join Sky Cinema in Germany and Italy in 2022. All other Sky customers will be able to subscribe to Paramount+ as an add-on to their account.

Paramount+ features an expansive catalog of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME®, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Outside of the United States, the premium streaming service offers nearly 3,000 episodes of kids’ content, 1,000 episodes of reality, more than 500 films, and 2,500 hours of Paramount+ Originals, CBS and SHOWTIME® series, dramas, and sitcoms.

Titles that will become available through 2022 in the UK, Ireland, Italy and GSA include a collection of scripted, exclusive Paramount+ Originals and exciting new takes on iconic franchises, including HALO, The Offer and the new iCarly series. As the international home of SHOWTIME, the service will offer The Man Who Fell to Earth, Ripley, Super Pumped, and American Gigolo, in addition to popular titles from ViacomCBS, such as Kamp Koral: SpongeBob’s Under Years, Star Trek: Prodigy, and MTV Unplugged. The service will also feature a collection of new movie premieres and fan favorites from Paramount Pictures such as films from the Mission Impossible and Transformer franchises.

In addition, ViacomCBS and Sky reached a multi-year extension for carriage of ViacomCBS’ linear channels — including Comedy Central, MTV and Nickelodeon — in the UK, Ireland, Italy and GSA. The channels will be complemented by a strong selection of box sets, giving customers the flexibility to watch the content they love whenever and wherever they want.

ViacomCBS renewed its multi-year agreement with Sky as an ad sales partner for all platforms and channels in the UK and Italy. Sky Media will continue to handle ad sales across the ViacomCBS portfolio of channels, including Channel 5 in the UK, where ViacomCBS and Channel 5 will benefit from Sky Media’s market-leading innovation in addressable advertising.

Other terms of the agreements were not disclosed.

Paramount+ will also be available direct-to-consumer in UK, Ireland, Italy and GSA through the Paramount+ app for iOS and Android and across supported connected TV devices and OTT platforms. Pricing and local content offering will be announced at a later date.

About Paramount+

Paramount+ is a global digital subscription video streaming service from ViacomCBS that features a mountain of premium entertainment for audiences of all ages. Internationally, the streaming service features an expansive library of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Launched on March 4, 2021, the service is currently available in the U.S., Canada, Latin America, and the Nordics, with Australia to launch August 11, 2021. By the end of 2021, ViacomCBS will have launched Paramount+ in 25 markets, ramping to 45 markets by the end of 2022.

For more information about Paramount+, please visit www.paramountplus.com and follow @ParamountPlus on social platforms.

About ViacomCBS Networks International (VCNI)

ViacomCBS Networks International (VCNI), a unit of ViacomCBS Inc. (NASDAQ: VIAC), is comprised of many of the world’s most iconic consumer brands. Its portfolio includes Channel 5, Telefe, Network 10, Nickelodeon, MTV, Comedy Central, BET, Paramount Network, as well as streaming services Paramount+ and PlutoTV, and ViacomCBS International Studios, among others. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution, and advertising solutions for partners on five continents and across more than 180 countries.

VIAC-IR

About Sky

Sky is Europe’s leading media and entertainment company and is part of Comcast Corporation, a global media and technology company. Across six countries, we connect our 23 million customers to the best entertainment, sports, news and arts including our own award-winning original content.

Our technology, including the market leading Sky Q, connects people to everything they love – with entertainment from Sky TV, Netflix, Disney+, Amazon Prime Video and BBC iPlayer, and apps like Spotify, YouTube, BBC Sounds, Highbrow, Peloton, Fiit, and more, in one place, easy. Our streaming service NOW brings viewers all the enjoyment of Sky with the flexibility of a contract-free service. Through our new B2B broadband provider, Sky Connect, we offer superfast broadband with business-grade 4G back-up to small businesses in the UK.

Building on the success of Sky Originals like Chernobyl, Gangs of London and Brassic, we are doubling our investment in original content by 2024 through Sky Studios. Sky News provides impartial and trustworthy journalism for free, Sky Arts is the UK’s only dedicated free-to-air arts channel making the arts accessible for everyone and Sky Sports, our leading sports broadcasting service, brings customers some of the biggest and best global sporting events from the Premier League to Formula 1 and everything in-between.Our new TV and movie studio, Sky Studios Elstree, which will open in 2022, is expected to create over 2,000 new jobs and generate an additional £3 billion of production investment in the UK over the first five years.

We believe that we can be a force for good in the communities in which we operate. We’re committed to being Europe’s first net zero carbon entertainment company by 2030 and we’re proud to be a Principal Partner and Media Partner of COP26. We take pride in our approach to diversity and inclusion: we’ve been recognised by The Times and Stonewall for our commitment to diversity and we’ve set ambitious 2025 targets to continue to increase diversity and representation. We’re also committed to investing £30million across our markets over three years to improve our approach to diversity and inclusion, and to tackle racial injustice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ViacomCBS Networks International

Kate Laverge
Senior Vice President, Communications
1-347.754.1677
kate.laverge@viacomcbs.com

Ashley Priest
Director, Communications
1-646-285-6081
Ashley.priest@viacomcbs.com

Sky

Andrew Swailes
Group Director of Corporate Communications
+44 7975 688993
andrew.swailes@sky.uk

Stuart Mawhinney
Head of Corporate Communications
+44 7772 696325
stuart.mawhinney@sky.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release

Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye